First-in-class approach
Inhibiting retinoid and rexinoid ligand formation upstream.
Investors
A first-in-class platform with multiple paths forward
Kayothera connects differentiated pathway biology, oral small-molecule development, and a focused multi-program pipeline.
Request investor materialsCompany thesis
Disciplined development around a differentiated target class
Program breadth
Three programs across major disease areas.
Scientific foundation
Peer-reviewed evidence supporting the pathway rationale.
Milestone focus
A development path connected to program-specific evidence.
Pipeline snapshot
Three programs. One biological foundation.
Retinoid synthesis / ALDH1a3-related biology
Rexinoid pathway / ALDH1a1-related biology
ALDH1a2 / retinoic acid synthesis / Sertoli cells
Milestones + roadmap
Progress mapped to development priorities
Completed milestones
AdvisoryClinical Advisory Board expansion
Key opinion leaders in beta-cell health and type 2 diabetes joined the Clinical Advisory Board.
ScienceAnti-tumor immunity research
New research and news advanced understanding of retinoic acid signaling in cancer immunity.
PublicationFoundational iScience research
Research on retinoid nuclear receptor pathway antagonists through targeting ALDH1A3 was published.
PipelineKAYO-1732 nominated
KAYO-1732 was selected as a development candidate for type 2 diabetes and cardiometabolic indications.
RecognitionADA Innovation Challenge
Kayothera was recognized as a winner of the American Diabetes Association Innovation Challenge.
PublicationJEM review published
A major review connected retinoid signaling with cancer and metabolic syndromes.
Forward roadmap
Platform validation
Build evidence around retinoid and rexinoid pathway inhibition.
Lead program selection
Advance program-specific small molecules and development priorities.
Preclinical development
Evaluate selected candidates in development-enabling studies.
IND-enabling preparation
Prepare development packages subject to study outcomes and strategy.
Clinical translation
Translate the platform subject to outcomes, regulatory feedback, funding, and company strategy.
Forward-looking development priorities are subject to study outcomes, regulatory feedback, funding, and company strategy.
JEMJournal of Experimental Medicine
Peer reviewed2024 / Review
Featured peer-reviewed foundation
The pathogenic role of retinoid nuclear receptor signaling in cancer and metabolic syndromes
A major review connecting retinoid nuclear receptor signaling to cancer biology, metabolic dysfunction, diabetes, obesity, and emerging therapeutic inhibition strategies.
Read the publicationFunding + recognition
Supported by an established life sciences ecosystem
01BioAdvance
02NJHF
03WRF Capital
047G BioVentures
05Andy Hill CARE FundGrant funding
Investor inquiries